Odyssey Therapeutics, Inc. Common Stock (ODTX) Stock
NYSE · ODTX
24.38
Fundamentals
Market cap
$1.17B
Price / Earnings ratio
-7.5x
Price / Sales ratio
375.0x
Price / Book ratio
2.6x
Return on assets
N/A
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. The company is led by an experienced team of drug discovery and development experts and leverages capabilities in immunobiology, medicinal and computational chemistry, protein biochemistry, structural biology, genetics, and pharmacology to identify and target key signaling pathways that drive disease.
SectorHealthcare
IndustryBiotechnology
Employees100
CEODr. Gary D. Glick Ph.D.
IPO DateMay 8, 2026
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Gary D. Glick Ph.D. | Founder, President, CEO & Director | 1962 |
| Mr. Jason Haas M.B.A. | Chief Financial Officer | 1968 |
| Mr. Collin Todd | Senior Vice President of Strategy & Business Development | 1992 |
| Prof. Eicke Latz M.D., Ph.D. | Scientific Co-Founder | — |
| Dr. Kim Lewis Ph.D. | Scientific Co-Founder | — |
| Dr. Felix Meissner Ph.D. | Scientific Co-Founder | — |
| Dr. Florian.I Schmidt Ph.D. | Scientific Co-Founder | — |
| Ms. Jolie M. Siegel J.D. | Executive VP, General Counsel & Secretary | 1977 |
| Dr. Natalie Dales Ph.D. | Chief of Research Operations & Portfolio Strategy | 1970 |
| Dr. Joseph McDonald Ph.D. | Chief Data Officer | — |
Fundamentals
Valuation
Market cap$1.17B
Price-to-sales ratio374.97
Price-to-book value2.65
Price-earnings ratio-7.50
Return on EquityN/A
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-48.93
Income Statement
Average volume227,322
EBITDA$-144.65M
1 year high (52w)$29.05
1 year low (52w)$15.10
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



